# Wysa vs. Cognoa: Business Comparison
## AI-Powered Healthcare Platforms - Executive Overview

**Date:** November 2025  
**Document Type:** High-Level Business Comparison

---

## SIDE-BY-SIDE COMPARISON

| **Aspect** | **Wysa** | **Cognoa** |
|-----------|----------|------------|
| **Core Product** | AI-powered mental health chatbot providing 24/7 emotional support and CBT therapy | FDA-authorized AI diagnostic tool for autism in children (18-72 months) |
| **Primary Service** | Conversational AI therapy, mood tracking, guided meditation, anxiety/depression support | Autism diagnosis aid combining parent questionnaires, physician input, and video analysis |
| **Business Model** | B2B (Primary) + B2C (Secondary) | B2B2C (Physician-prescribed) |
| **Target Market** | • Employers (corporate wellness)<br>• Health plans/insurers<br>• Healthcare systems<br>• Individual consumers | • Pediatricians/primary care physicians<br>• Parents of children with developmental concerns<br>• Healthcare systems |
| **Revenue Model** | • B2B: Per-employee-per-month (PEPM) subscription<br>• B2C: Freemium + premium subscriptions ($30-70/month) | • Per-diagnosis fee ($500-$1,500)<br>• Insurance reimbursement (Medicaid, commercial) |
| **Geographic Reach** | Global (105 countries) | United States (FDA-regulated) |
| **Users/Impact** | 6 million+ users, 11 million lives covered through B2B | Thousands of diagnoses, expanding coverage |
| **Total Funding** | $30.5M+ (Series B: $20M in 2022) | $30M+ (estimated) |
| **Founded** | 2015 | 2013 |
| **Headquarters** | Boston, MA / Bangalore, India | Palo Alto, CA |

---

## 1. CORE PRODUCT/SERVICE

### Wysa
**What They Offer:**
- AI chatbot providing mental health support using evidence-based CBT techniques
- 24/7 availability with no appointments needed
- Anonymous access option to reduce stigma
- Escalation to human therapists when needed
- Mood tracking, meditation, sleep programs, anxiety/depression management

**Key Features:**
- 1 billion+ AI conversations processed
- 2 million+ CBT sessions delivered
- 45+ peer-reviewed clinical studies
- 91% user satisfaction rate

### Cognoa
**What They Offer:**
- Canvas Dx: First FDA-authorized AI diagnostic aid for autism
- Combines machine learning, video analysis, and clinical questionnaires
- Helps pediatricians diagnose autism earlier and more accurately
- Reduces diagnosis wait time from years to weeks

**Key Features:**
- 95.2% Negative Predictive Value (can rule out autism with high confidence)
- FDA Class II medical device authorization (June 2021)
- Addresses critical access gap in autism diagnosis
- Targets children 18-72 months old

---

## 2. TARGET MARKET

### Wysa

**Primary (B2B):**
- **Employers:** Corporate wellness programs (Accenture, Colgate-Palmolive)
- **Health Plans:** Insurance companies (MassMutual - first U.S. insurer partner)
- **Healthcare Systems:** Employee Assistance Programs (EAPs)
- **Educational Institutions:** Student mental health support

**Secondary (B2C):**
- Individual users seeking affordable mental health support
- Global consumer base across 105 countries

**Market Size:**
- 1 in 5 adults experience mental illness annually
- 160 million Americans live in mental health professional shortage areas
- Mental health AI market: $2.7B in funding (2024), growing 38% YoY

### Cognoa

**Primary (B2B2C):**
- **Pediatricians:** Primary care physicians who prescribe the diagnostic tool
- **Parents/Caregivers:** End users who complete assessments
- **Healthcare Systems:** Integrated into primary care workflows

**Market Size:**
- 1 in 36 children diagnosed with autism (CDC 2023)
- Average diagnosis wait time: 3-4 years (traditional methods)
- Massive unmet need for accessible, early autism diagnosis

---

## 3. REVENUE MODEL

### Wysa

**B2B Revenue (Primary):**
- Per-employee-per-month (PEPM) subscription model
- Enterprise licensing based on organization size
- Tiered pricing for different feature access
- Majority of revenue from B2B partnerships

**B2C Revenue (Secondary):**
- Freemium model with basic features free
- Premium subscriptions: $30-70/month
- In-app purchases for additional content

**Pricing Strategy:**
- Focus on enterprise value proposition (ROI, productivity gains)
- 33% reduction in lost-time days for employers
- Lower cost than traditional therapy

### Cognoa

**Per-Diagnosis Model:**
- Estimated $500-$1,500 per assessment
- Physician prescribes, insurance covers

**Insurance Reimbursement:**
- Highmark Insurance (first commercial payer)
- Wyoming Medicaid (expanding to other states)
- Working on broader payer coverage

**Value Proposition:**
- Reduces wait times from years to weeks
- Increases access to diagnosis in primary care
- Lower cost than specialist evaluation
- Enables earlier intervention

---

## 4. KEY DIFFERENTIATORS

### Wysa

**Unique Advantages:**
1. **Clinical Validation:** 45+ peer-reviewed studies (more than most competitors)
2. **B2B Focus:** Strong enterprise partnerships vs. pure consumer play
3. **Global Scale:** 105 countries, 6M+ users
4. **Anonymous Access:** Reduces stigma, increases engagement
5. **Hybrid Model:** AI-first with human therapist backup
6. **Evidence-Based:** Structured CBT pathways, not just conversation
7. **No FDA Regulation:** Positioned as wellness tool, faster to market

**Competitive Position:**
- More clinical than wellness apps (Headspace, Calm)
- More accessible than traditional therapy (Talkspace, BetterHelp)
- Stronger B2B focus than AI competitors (Woebot, Youper)

### Cognoa

**Unique Advantages:**
1. **FDA Authorization:** First and only FDA-cleared AI autism diagnostic
2. **Early Diagnosis:** Targets 18-72 months (earlier than traditional 4-5 years)
3. **Primary Care Access:** Deployed in pediatrician offices, not specialist-only
4. **High Accuracy:** 95.2% NPV for ruling out autism
5. **Reduces Wait Times:** Months/years to weeks
6. **Insurance Coverage:** Reimbursable by Medicaid and commercial payers
7. **Strong Regulatory Moat:** Extremely difficult for competitors to replicate

**Competitive Position:**
- Only FDA-authorized AI diagnostic for autism
- Complements (not replaces) specialist evaluation
- Addresses massive access gap in autism diagnosis

---

## 5. BUSINESS METRICS

### Wysa

| Metric | Value |
|--------|-------|
| **Total Users** | 6 million+ |
| **Geographic Reach** | 105 countries |
| **Lives Covered (B2B)** | 11 million |
| **Total Funding** | $30.5M+ |
| **Latest Round** | Series B: $20M (July 2022) |
| **Lead Investors** | HealthQuad, W Health Ventures, Google Assistant Investments |
| **AI Conversations** | 1 billion+ |
| **CBT Sessions** | 2 million+ |
| **User Satisfaction** | 91% find Wysa helpful |
| **Workplace Impact** | 33% reduction in lost-time days |
| **Clinical Studies** | 45+ peer-reviewed publications |
| **Enterprise Clients** | Accenture, Colgate-Palmolive, MassMutual |

### Cognoa

| Metric | Value |
|--------|-------|
| **FDA Status** | Class II Medical Device (De Novo pathway) |
| **FDA Authorization** | June 2021 |
| **Total Funding** | $30M+ (estimated) |
| **Clinical Performance** | 95.2% Negative Predictive Value |
| **Target Age** | 18-72 months |
| **Insurance Coverage** | Highmark (commercial), Wyoming Medicaid |
| **Pricing** | $500-$1,500 per assessment |
| **Market Opportunity** | 1 in 36 children (CDC 2023) |
| **Wait Time Reduction** | Years → Weeks |
| **Commercialization Partner** | EVERSANA |

---

## SUMMARY: WHICH MODEL FOR YOUR CLIENT?

### Choose Wysa-Like Model If:
✅ Want global scalability  
✅ Prefer B2B enterprise focus  
✅ Avoid FDA regulatory pathway  
✅ Target mental health/wellness market  
✅ Faster time to market (18-30 months)  
✅ Lower investment ($2-5M)  

### Choose Cognoa-Like Model If:
✅ Have significant funding ($8-15M+)  
✅ Can commit to 4-6 year timeline  
✅ Want strong regulatory moat (FDA)  
✅ Target specific diagnostic need  
✅ Willing to navigate insurance reimbursement  
✅ U.S.-focused market acceptable  

---

**Document Version:** 1.0  
**Prepared for:** Client Business Review  
**Focus:** Business model comparison only (excludes technical implementation details)

